225Ac was conjugated to the monoclonal antibody J591 targeting PSMA in prostate cancer is under investigation in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT03276572). The gene discussed is FOLH1; the disease is prostate carcinoma.